The U.S. FDA set May 31 as the first date for a hearing on CBD as the government agency looks to potentially legalize the cannabis compound as an additive in food and drinks.
At the meeting — which will take place at the agency’s headquarters in Silver Spring, Md. — the agency will obtain “scientific data and information about the safety, manufacturing, product quality, marketing, labeling and sale” of products that contain cannabis or cannabis-derived compounds, according to a document uploaded in the Federal Register Tuesday.
The public hearing will allow people to present data on the safety of the consumption and use of CBD.
In December last year, hemp — and any part or derivative of the plant — was legalized for sale in the U.S. This includes the compound CBD (cannabidiol).
Unlike THC (tetrahydrocannabinol), the compound CBD is not psychoactive and does not give users the feeling of being “high.” CBD has become known for its calming effects, with many users saying it helps them manage pain.
Since it was legalized in December 2018, CBD has gained popularity, with companies including Walgreens and CVS announcing last month they would begin selling CBD products at stores in eight states.
In recent months, the FDA has cracked down on CBD food products and dietary supplements, as the agency has said there is not enough research on the cannabis-derived compound.
The NYC Department of Health banned CBD as an additive in food and drink products at restaurants and bars in February because it has not been deemed safe to eat.